Plain-English translation of NCT05796570 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This research study is testing whether combined with — two medications given together — can prevent blood cancers like acute myeloid leukemia and myelodysplastic syndrome from returning after a stem cell transplant in children and young adults. The medication has already shown promise in adult patients, and this study aims to see if it works well and is safe for younger patients too.
Even after a successful stem cell transplant, blood cancers can sometimes come back, which is a major concern for young patients. This study is trying to find out if this medication combination can lower the risk of cancer relapse and help more patients stay in remission long-term.
You likely qualify if…
You likely don't qualify if…
You would receive the two medications in cycles over 6 months following your stem cell transplant, with the first cycle starting 40 to 120 days after your transplant. Each cycle lasts 28 days, and you'll receive for 6 days and for 5 days per cycle. You'll have regular clinic visits, blood tests, and bone marrow biopsies (which are standard care) throughout the 6-month treatment period, and then return for follow-up visits every 6 months for 2 years after your transplant to make sure the treatment is working and you're doing well.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States